Janus Henderson Group PLC Sells 1,974,566 Shares of Immunic, Inc. (NASDAQ:IMUX)

Janus Henderson Group PLC cut its position in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 27.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,099,278 shares of the company's stock after selling 1,974,566 shares during the period. Janus Henderson Group PLC owned approximately 5.66% of Immunic worth $8,439,000 at the end of the most recent quarter.

Separately, Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Immunic Trading Up 3.1 %

Shares of IMUX traded up $0.04 during mid-day trading on Monday, hitting $1.32. The company's stock had a trading volume of 573,703 shares, compared to its average volume of 631,521. The company's 50-day moving average is $1.32 and its 200-day moving average is $1.34. Immunic, Inc. has a 52-week low of $0.97 and a 52-week high of $2.11. The firm has a market capitalization of $118.90 million, a price-to-earnings ratio of -1.07 and a beta of 1.89.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright began coverage on shares of Immunic in a research note on Monday, November 25th. They set a "buy" rating and a $10.00 price target for the company. Leerink Partners reissued an "outperform" rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a "strong-buy" rating in a research report on Monday, September 16th. Leerink Partnrs raised shares of Immunic to a "strong-buy" rating in a research report on Monday, September 9th. Finally, StockNews.com cut shares of Immunic from a "hold" rating to a "sell" rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Immunic presently has a consensus rating of "Buy" and a consensus price target of $11.80.

Insider Transactions at Immunic

In other news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the purchase, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 3.00% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.